Incyte Genomics Inc (INCY) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with N...
Incyte Genomics Inc (INCY) currently trades at a P/E ratio of 18.37 (historical range: 13.32–663.64, median: 388.89), placing it at the 44th percentile — near its historical average, P/S ratio of 4.91 (range: 2.48–5.01, 98th percentile — expensive relative to its history).
Over the historical period (2024-08-30 to 2026-08-28), Incyte Genomics Inc's P/E ratio has contracted by 88% over the observed period (from an average of 456.6 to 56.2).
Incyte Genomics Inc appears slightly overvalued relative to its historical range, with most valuation metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 18.37 | 13.32 | 388.89 | 663.64 | 44th | near its historical average |
| P/S Ratio | 4.91 | 2.48 | 3.80 | 5.01 | 98th | expensive relative to its history |